Christopher J. Moreau
Chief Executive Officer and Director
Mr. Moreau is the CEO of Algernon Pharmaceuticals Inc. and a member of the company’s board of directors. With over 30 years of executive management experience, including 15 years in CEO roles, he has proven achievements in operations management, acquisitions, licensing, and integration. Mr. Moreau also has significant experience managing biotechnology research programs, and a deep expertise in business development and capital markets, having raised more than $50 million in equity financings. He is a highly skilled communicator and sought-after speaker and has been featured on numerous business television and social media interviews, and is a returning guest lecturer at the University of East London, Pharmacology program.
Dr. Christopher Bryan, Ph.D.
Vice President Research & Operations
Dr. Christopher Bryan graduated from the University of Toronto, with a Ph.D. in organic chemistry and brings significant skills and experience to Algernon. His background as a scientist and senior manager includes the synthesis of hundreds of novel small molecules as potential therapeutic agents, the coordination of regional commercial teams and internal departments (i.e., marketing, R&D, manufacturing, sales and regulatory affairs), and the management of multiple strategic relationships including those involving key opinion leaders. Since assuming his current role, Dr. Bryan has overseen the company’s clinical and preclinical programs, including investigations into fibrotic and infectious diseases as well as neurological indications.
James Kinley, CPA, CA
Chief Financial Officer & Director
Mr. Kinley is a Certified Professional Accountant (“CPA, CA”) with over 15 years of experience in building, leading, and advising corporations through their daily operations as well as on complex restructurings, mergers, acquisitions, and capital markets transactions. He is also accomplished in structuring and negotiating favorable terms with commercial and investment banks. He was previously the CFO for Medicure Inc. (TSX-V: MPH), another Canadian publicly traded pharmaceutical company, a position he held for nearly 10 years.
Dr. Ahmad Khalil, MD, PhD
Dr. Ahmad Khalil, MD, PhD has extensive biopharmaceutical experience bringing drugs into clinical trials over the past 20 years, acting in the capacities of Medical Director, Medical Monitor, and Clinical Consultant for a variety of companies. He is a member of the Harvard Medical School Postgraduate Association, the Canadian Medical Association, the University of Montreal General Professor Syndicate, and the American Heart Association Professional Membership & Cardiovascular Science Councils.